Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Giuseppe Fallara, Charlotte Alverbratt, Hans Garmo, Hanna Vikman, Marie Hjelm Eriksson, Ingela Franck Lissbrant & Pär Stattin. (2021) Time on treatment with abiraterone and enzalutamide in the Patient-overview Prostate Cancer in The National Prostate Cancer Register of Sweden. Acta Oncologica 60:12, pages 1589-1596.
Read now
Read now
Articles from other publishers (10)
Gérard de Pouvourville, David Cunningham, Frank-Ulrich Fricke, Peter Lindgren, Lorenzo Mantovani, Linda A. Murphy, Oriol Solà-Morales, Jorge Mestre-Ferrandiz & Ron Akehurst. (2023) Across-Country Variations of Real-World Data and Evidence for Drugs: A 5-European-Country Study. Value in Health 26:4, pages 3-10.
Crossref
Crossref
Giuseppe Fallara, Ingela Franck Lissbrant, Johan Styrke, Francesco Montorsi, Hans Garmo & Pär Stattin. (2020) Observational study on time on treatment with abiraterone and enzalutamide. PLOS ONE 15:12, pages e0244462.
Crossref
Crossref
Zandra Engelbak Nielsen, Stefan Eriksson, Laurine Bente Schram Harsløf, Suzanne Petri, Gert Helgesson, Margrete Mangset & Tove E. Godskesen. (2020) Are cancer patients better off if they participate in clinical trials? A mixed methods study. BMC Cancer 20:1.
Crossref
Crossref
Kelly Baillie, Tanja Mueller, Jiafeng Pan, Jennifer Laskey, Marion Bennie, Christine Crearie, Kimberley Kavanagh, Samantha Alvarez‐Madrazo, David Morrison, Julie Clarke, Aileen Keel, David Cameron, Olivia Wu, Amanj Kurdi & Robert J. Jones. (2020) Use of record linkage to evaluate treatment outcomes and trial eligibility in a real‐world metastatic prostate cancer population in Scotland. Pharmacoepidemiology and Drug Safety 29:6, pages 653-663.
Crossref
Crossref
Ahmad S. Halwani, Kelli M. Rasmussen, Vikas Patil, Catherine C. Li, Christina M. Yong, Zachary Burningham, Sumati Gupta, Sujata Narayanan, Shih-Wen Lin, Susheela Carroll, Shivani K. Mhatre, Julie N. Graff, Robert Dreicer & Brian C. Sauer. (2020) Real-world practice patterns in veterans with metastatic castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations 38:1, pages 1.e1-1.e10.
Crossref
Crossref
Javier Puente, Aranzazu González-del-Alba, Núria Sala-Gonzalez, María José Méndez-Vidal, Alvaro Pinto, Ángel Rodríguez, José Miguel Cuevas Sanz, Jacobo Rodrigo Muñoz del Toro, Eduardo Useros Rodríguez, Ángela García García-Porrero & Sergio Vázquez. (2019) Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO). BMC Cancer 19:1.
Crossref
Crossref
Omar Abdel-Rahman. (2019) Comparison of outcomes of radiotherapy-treated localized prostate cancer patients within a clinical trial setting versus real-life setting. Future Oncology 15:11, pages 1269-1277.
Crossref
Crossref
M. Koninckx, J. L. Marco, I. Pérez, M. T. Faus, V. Alcolea & F. Gómez. (2018) Effectiveness, safety and cost of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world data analysis. Clinical and Translational Oncology 21:3, pages 314-323.
Crossref
Crossref
E. David Crawford, Neal D. Shore, Daniel P. Petrylak, Celestia S. Higano & Charles J. Ryan. (2017) Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility. Therapeutic Advances in Medical Oncology 9:5, pages 319-333.
Crossref
Crossref
Joice Rocha, Armen G. Aprikian, Marie Vanhuyse, Fabio L. Cury, Jason Hu, Noémie Prévost & Alice Dragomir. (2017) Impact of abiraterone acetate with and without prior docetaxel chemotherapy on the survival of patients with metastatic castration-resistant prostate cancer: a population-based study. CMAJ Open 5:1, pages E265-E272.
Crossref
Crossref